Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TML-FIR-19
- Development stage
- Preclinical
- Lead developer
- Themis Medicare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TML-FIR-19 is a preclinical-stage nonsystemic antibiotic candidate being developed by Themis Medicare. It utilizes a Novel Drug Delivery System (NDDS) specifically engineered for targeted delivery to the colon via oral administration. By concentrating the antibiotic's activity within the colon and minimizing systemic absorption, TML-FIR-19 is designed to treat localized gastrointestinal conditions or infections while reducing the risk of systemic side effects and preserving the non-target systemic microbiome.
Beyond the preview
Go deeper on TML-FIR-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TML-FIR-19.